Search bioRxiv⌕ Search

Biology subjects

Uroda, T.

Publications and source records attributed to Uroda, T..

2 recordsLinked to original sources

Organisational principles of long non-coding RNAs revealed by exon deletion

Long non-coding RNAs (lncRNAs) regulate cell phenotypes in health and disease, yet how function is encoded in their sequence remains poorly understood. Current models propose a modular architecture composed of discrete functional elements, but this is based on a limited set of paradigmatic examples and methods for mapping function to sequence are limited in scope and resolution. Here, we establish a high-throughput CRISPR-Cas9 strategy for dissecting lncRNA functional architecture at exon resolution. Using cell fitness as a phenotypic readout, we screened 358 exons from 107 lncRNAs across four human cell lines. We report that (1) a large proportion of exons have no detectable function, (2) a minority of exons are functional in any given cell line (19-111 exons), equivalent to one-fifth of total transcript nucleotides on average, and (3) functionality is enriched towards the 5 end of the transcript. We developed a database of putative lncRNA functional elements, ElementaLdb, and demonstrated through statistical and experimental analyses that lncRNA function depends on transposable elements, microRNA response elements and RNA binding protein sites. These sub-genic functional maps expand the catalogue of experimentally defined lncRNA functional elements by an order of magnitude, illuminate molecular mechanisms and broadly support a modular organisation for lncRNAs.

genomics↗

Robust CRISPR Screens Identify TPL1 as a Novel Long Noncoding RNA Driving Triple-Negative Breast Cancer Hallmarks

Despite the growing catalog of long noncoding RNAs (lncRNAs), the functional roles of their vast majority in cancer remain poorly defined. To systematically explore lncRNA dependencies in triple-negative breast cancer (TNBC), we compiled a comprehensive annotation by merging GENCODE, BIGTranscriptome, and MiTranscriptome databases and performed a CRISPR-Cas9 deletion screen targeting 1,029 TNBC-enriched lncRNAs. The screen revealed several essential lncRNAs and those modulating doxorubicin sensitivity, with TPL1 emerging among top hits. TPL1 silencing significantly impaired TNBC cell proliferation in both 2D and 3D cultures and reduced invasive capacity in an organ-on-chip model. Transcriptomic and proteomic profiling following TPL1 knockdown revealed downregulation of genes involved in ECM-receptor interaction, focal adhesion, cell migration, and PI3K-Akt signaling. Mechanistically, TPL1 directly interacted with key proteins including EIF4B, MDM2, TARBP2, TLE5, and GTPase RAN, suggesting TPL1 could regulate RNA processing, transcriptional repression, and translation, as well as modulate GTPase signaling pathways. Additionally, TPL1 functioned as a competing endogenous RNA (ceRNA), sequestering miR-10396b-5p, miR-486-3p, and miR-450a-2-3p, among others, thereby modulating expression of pro-tumorigenic targets. Clinically, TPL1 was significantly overexpressed in TNBC tissues, particularly in the BLIS subtype. Collectively, our findings highlight TPL1 as a key regulator of TNBC molecular networks and a promising therapeutic target.

cancer biology↗